187235-28-5 Usage
Description
(6S)-6-[(4-benzyloxyphenyl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine is a complex chemical compound characterized by its unique structure, which includes a nitro group, a benzyloxyphenyl group, and an imidazo[2,1-b][1,3]oxazine ring. (6S)-6-[(4-benzyloxyphenyl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine is a potential pharmaceutical agent with the ability to interact with biological systems in a specific manner, suggesting various biological activities and potential applications in drug development or medicinal chemistry. Further research is necessary to fully understand its potential uses and properties.
Uses
Used in Pharmaceutical Industry:
(6S)-6-[(4-benzyloxyphenyl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine is used as a potential pharmaceutical agent for its ability to interact with biological systems in a specific way. Its unique structure and potential biological activities make it a compound of interest for further study in drug development and medicinal chemistry.
Used in Medicinal Chemistry:
(6S)-6-[(4-benzyloxyphenyl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine is used as a compound of interest in medicinal chemistry due to its complex structure and potential for various biological activities. Its study may lead to the discovery of new therapeutic agents or a better understanding of biological interactions at the molecular level.
Check Digit Verification of cas no
The CAS Registry Mumber 187235-28-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,7,2,3 and 5 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 187235-28:
(8*1)+(7*8)+(6*7)+(5*2)+(4*3)+(3*5)+(2*2)+(1*8)=155
155 % 10 = 5
So 187235-28-5 is a valid CAS Registry Number.
187235-28-5Relevant articles and documents
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6 S)-2-nitro-6-{[4-(trifluoromethoxy) benzyl]oxy}-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazine (PA-824)
Thompson, Andrew M.,Sutherland, Hamish S.,Palmer, Brian D.,Kmentova, Iveta,Blaser, Adrian,Franzblau, Scott G.,Wan, Baojie,Wang, Yuehong,Ma, Zhenkun,Denny, William A.
supporting information; experimental part, p. 6563 - 6585 (2011/12/02)
New analogues of antitubercular drug PA-824 were synthesized, featuring alternative side chain ether linkers of varying size and flexibility, seeking drug candidates with enhanced metabolic stability and high efficacy. Both α-methyl substitution and removal of the benzylic methylene were broadly tolerated in vitro, with a biaryl example of the latter class exhibiting an 8-fold better efficacy than the parent drug in a mouse model of acute Mycobacterium tuberculosis infection and negligible fragmentation to an alcohol metabolite in liver microsomes. Extended linkers (notably propenyloxy, propynyloxy, and pentynyloxy) provided greater potencies against replicating M. tb (monoaryl analogues), with propynyl ethers being most effective under anaerobic (nonreplicating) conditions (mono/biaryl analogues). For benzyloxybenzyl and biaryl derivatives, aerobic activity was maximal with the original (OCH2) linker. One propynyloxy-linked compound displayed an 89-fold higher efficacy than the parent drug in the acute model, and it was slightly superior to antitubercular drug OPC-67683 in a chronic infection model.
